Plasma magnesium and the risk of new-onset hyperuricaemia in hypertensive patients

Abstract

We aimed to evaluate the relationship of plasma Mg with the risk of new-onset hyperuricaemia and examine any possible effect modifiers in hypertensive patients. This is a post hoc analysis of the Uric acid (UA) Sub-study of the China Stroke Primary Prevention Trial (CSPPT). A total of 1685 participants were included in the present study. The main outcome was new-onset hyperuricaemia defined as a UA concentration ≥417 μmol/l in men or ≥357 μmol/l in women. The secondary outcome was a change in UA concentration defined as UA at the exit visit minus that at baseline. During a median follow-up duration of 4.3 years, new-onset hyperuricaemia occurred in 290 (17.2 %) participants. There was a significantly inverse relation of plasma Mg with the risk of new-onset hyperuricaemia (per sd increment; OR 0.85; 95 % CI 0.74, 0.99) and change in UA levels (per sd increment; β -3.96 μmol/l; 95 % CI -7.14, -0.79). Consistently, when plasma Mg was analysed as tertiles, a significantly lower risk of new-onset hyperuricaemia (OR 0.67; 95 % CI 0.48, 0.95) and less increase in UA levels (β -8.35 μmol/l; 95 % CI -16.12, -0.58) were found among participants in tertile 3 (≥885.5 μmol/l) compared with those in tertile 1 (<818.9 μmol/l). Similar trends were found in males and females. Higher plasma Mg levels were associated with a decreased risk of new-onset hyperuricaemia in hypertensive adults.